Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 12-Month High – Should You Buy?

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $37.35 and last traded at $36.2480, with a volume of 22298869 shares. The stock had previously closed at $35.52.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TEVA. Scotiabank raised their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. The Goldman Sachs Group lifted their target price on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. JPMorgan Chase & Co. upped their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Jefferies Financial Group increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Bank of America lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $36.00.

Teva Pharmaceutical Industries Trading Up 2.0%

The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The firm has a market cap of $41.58 billion, a price-to-earnings ratio of 30.21, a price-to-earnings-growth ratio of 2.02 and a beta of 0.70. The business’s 50-day moving average price is $30.93 and its two-hundred day moving average price is $23.53.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 48.20%. Teva Pharmaceutical Industries’s revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. This represents a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 77,400 shares of the stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the transaction, the director owned 367,600 shares in the company, valued at $11,116,224. This trade represents a 17.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 622,060 shares of company stock worth $17,076,965 in the last three months. Company insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently modified their holdings of the stock. Grove Bank & Trust increased its position in Teva Pharmaceutical Industries by 300.0% during the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares during the last quarter. Cromwell Holdings LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares during the last quarter. Advisors Asset Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at $41,000. Rothschild Investment LLC increased its holdings in shares of Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after buying an additional 1,348 shares during the last quarter. Finally, JFS Wealth Advisors LLC increased its holdings in shares of Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after buying an additional 2,000 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.